Development of a Human Antibody for T Cell Neoplasms
Author Information
Author(s): Pitaro Michele, Antonini Giovanni, Arcovito Alessandro, Buccisano Francesco, De Lauro Alfredo, Irno Consalvo Maria, Gallo Valentina, Giacon Noah, Mangiatordi Giuseppe Felice, Pacelli Maddalena, Pitaro Maria Teresa, Polticelli Fabio, Sorrenti Matteo, Venditti Adriano
Primary Institution: INBB – Istituto Nazionale Biostrutture e Biosistemi, Rome, Italy
Hypothesis
Can a recombinant human IgG1 monoclonal antibody targeting the TRBV5-1 segment of the T cell receptor be developed for treating mature T cell neoplasms?
Conclusion
The study successfully developed a human IgG1 monoclonal antibody that specifically targets T cells expressing the TRBV5-1 segment, offering a potential new treatment for mature T-cell neoplasms.
Supporting Evidence
- The antibody demonstrated high specificity for tumor T lymphocytes expressing TRBV5-1.
- SPR studies confirmed the antibody's binding affinity in the nanomolar range.
- Flow cytometry showed that the antibody selectively binds to T cells without affecting other blood components.
Takeaway
Scientists created a special antibody that can find and attach to bad T cells in certain cancers, helping to treat those diseases better.
Methodology
The study involved bioinformatic analysis, phage display to screen for specific antibodies, and various assays including surface plasmon resonance and flow cytometry to assess antibody binding.
Limitations
Potential emergence of neoplastic clones with different TCRs and downregulation of TCR expression could limit the effectiveness of the antibody.
Participant Demographics
Two patients with mature T-cell neoplasm (Sézary syndrome), one expressing TRBV5-1 and the other TRBV6-5.
Statistical Information
P-Value
300 ± 13 nM
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website